Suppr超能文献

基于自由能微扰的导向合成及其生物评价:取代喹啉衍生物作为小分子 L858R/T790M/C797S 突变型 EGFR 抑制剂,靶向治疗非小细胞肺癌(NSCLC)的耐药性。

Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).

机构信息

Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, MS 431004, India.

Department of Pharmaceutical Chemistry, Durgamata Institute of Pharmacy, Dharmapuri, Parbhani 431401, MS, India.

出版信息

Bioorg Chem. 2021 Oct;115:105226. doi: 10.1016/j.bioorg.2021.105226. Epub 2021 Jul 31.

Abstract

Two different schemes of novel substituted quinoline derivatives were designed and synthesized via simple reaction steps and conditions. A comparative molecular docking study was carried out on two different types of EGFR enzymes which include wild-type (PDB: 4I23) and T790M mutated (PDB: 2JIV) respectively. Compounds were also validated upon T790M/C797S mutated (PDB ID: 5D41) EGFR enzyme at the allosteric binding site. Free energy perturbations were carried out to determine the absolute binding free energy of a protein-ligand complex in the form of ΔG, which in turn provided 4ab and 5ad as the most potential contenders through the structural enhancement in the determined initial scaffolds. Anticancer activity of the synthesized derivatives was examined against HCC827, H1975 (L858R/T790M), A549, and HT-29 cell lines by standard MTT assay. Compound 4ad (6-chloro-2-(isoindolin-2-yl)-4-methylquinoline) has shown excellent inhibitory activities against mutant EGFR kinase with IC value 0.91 µM. The potency of compounds 4ab, 4ad and 5adwas compared throughan insilicoADMET study.

摘要

设计并合成了两种不同方案的新型取代喹啉衍生物,通过简单的反应步骤和条件进行。分别对两种不同类型的 EGFR 酶(包括野生型(PDB:4I23)和 T790M 突变型(PDB:2JIV))进行了比较分子对接研究。还在变构结合位点对 T790M/C797S 突变(PDB ID:5D41)EGFR 酶进行了化合物验证。通过自由能扰动来确定蛋白质-配体复合物的绝对结合自由能ΔG,从而通过确定初始支架中的结构增强,将 4ab 和 5ad 作为最有潜力的竞争者。通过标准的 MTT 测定法,对合成的衍生物对 HCC827、H1975(L858R/T790M)、A549 和 HT-29 细胞系的抗癌活性进行了检测。化合物 4ad(6-氯-2-(异吲哚啉-2-基)-4-甲基喹啉)对突变型 EGFR 激酶具有优异的抑制活性,IC 值为 0.91µM。通过计算机 ADMET 研究比较了化合物 4ab、4ad 和 5ad 的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验